eli lilly glp-1 drug Oral Orforglipron Is Approved for Obesity A new weight loss drug
Description
There is interest in GLP-1 agonists and their ability to either reduce atherosclerotic plaque burden or the potential for plaque disruption- recognized as a proximate cause of arterial thrombotic events
Experiments undertaken in 1964 showed more insulin secretion with oral versus intravenous (IV) glucose administration despite identical glucose concentrations, an effect coined the Incretin effect [10]
European Teratology Information Services Study (BMJ 2024) Design: Prospective observational cohort Sample: 168 GLP-1 RA-exposed pregnancies, compared with diabetic and obese reference groups Findings: Major birth defect rates: 2.6% (GLP-1 RA) vs
They will consider your medical history, current medications, and overall health
